Compare YQ & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | BCTX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 36.6M |
| IPO Year | 2020 | 2025 |
| Metric | YQ | BCTX |
|---|---|---|
| Price | $3.36 | $3.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.6K | ★ 140.4K |
| Earning Date | 09-08-2026 | 10-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $274.52 | N/A |
| Revenue Next Year | $29.79 | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.68 | $2.60 |
| 52 Week High | $6.45 | $14.68 |
| Indicator | YQ | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 51.04 |
| Support Level | $3.26 | $3.66 |
| Resistance Level | $3.68 | $4.49 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 32.01 | 47.67 |
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.